Andrew Guggenhime Sells 10,900 Shares of Dermira Inc. (DERM) Stock
Dermira Inc. (NASDAQ:DERM) CFO Andrew Guggenhime sold 10,900 shares of Dermira stock in a transaction on Tuesday, October 11th. The stock was sold at an average price of $34.34, for a total transaction of $374,306.00. Following the transaction, the chief financial officer now directly owns 16,016 shares of the company’s stock, valued at $549,989.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Andrew Guggenhime also recently made the following trade(s):
- On Monday, September 19th, Andrew Guggenhime sold 15,000 shares of Dermira stock. The stock was sold at an average price of $35.01, for a total transaction of $525,150.00.
- On Monday, September 12th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The stock was sold at an average price of $32.53, for a total transaction of $325,300.00.
- On Thursday, August 11th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The stock was sold at an average price of $31.02, for a total transaction of $310,200.00.
Shares of Dermira Inc. (NASDAQ:DERM) opened at 33.36 on Friday. The firm’s market capitalization is $1.18 billion. Dermira Inc. has a 52 week low of $17.42 and a 52 week high of $36.16. The firm has a 50 day moving average price of $33.45 and a 200-day moving average price of $29.93.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/14/andrew-guggenhime-sells-10900-shares-of-dermira-inc-derm-stock.html
Dermira (NASDAQ:DERM) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.03. Equities research analysts predict that Dermira Inc. will post ($3.46) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in DERM. Glenmede Trust Co. NA bought a new position in shares of Dermira during the second quarter valued at $170,000. AXA acquired a new stake in Dermira during the first quarter worth $1,911,000. Teachers Advisors Inc. increased its stake in Dermira by 1.9% in the first quarter. Teachers Advisors Inc. now owns 123,531 shares of the biopharmaceutical company’s stock worth $2,555,000 after buying an additional 2,278 shares during the period. American Century Companies Inc. acquired a new stake in Dermira during the second quarter worth $1,352,000. Finally, BlackRock Inc. increased its stake in Dermira by 1.0% in the first quarter. BlackRock Inc. now owns 49,260 shares of the biopharmaceutical company’s stock worth $1,018,000 after buying an additional 499 shares during the period. Institutional investors own 82.46% of the company’s stock.
Several research firms have commented on DERM. Needham & Company LLC reaffirmed a “positive” rating and set a $46.00 price objective on shares of Dermira in a research note on Monday, October 3rd. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. Finally, Leerink Swann reissued a “buy” rating on shares of Dermira in a research note on Wednesday, October 5th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Dermira currently has a consensus rating of “Buy” and an average target price of $41.00.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.